查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1463157

抗肥胖藥物市場、佔有率、規模、趨勢、產業分析報告：依作用機制、依產品、依分銷管道、依地區、依細分市場預測，2024-2032

Anti-Obesity Medication Market Share, Size, Trends, Industry Analysis Report, By Mechanism of Action (Centrally Acting Drugs, Peripherally Acting Drugs); By Product; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 117 Pages | 商品交期: 最快1-2個工作天內

價格

根據Polaris Market Research的最新研究，預計到2032年，全球抗肥胖藥物市場規模將達到734.7085億美元。 該報告提供了對當前市場動態的詳細見解，並對未來市場成長進行了分析。

抗肥胖藥物可用於改善個人的盈餘，特別是當飲食調整和身體活動等生活方式的改變不足以實現和維持健康體重時。 這些藥物透過多種機制發揮作用，包括調節新陳代謝、抑制脂肪吸收和抑制食慾。 醫療保健提供者通常會將其開給符合某些標準的患者，例如體重指數 (BMI) 高的患者或患有 2 型糖尿病等肥胖相關健康問題的患者。

受體重管理社會觀念變化、全球肥胖率上升以及藥物研究進展等因素的影響，抗肥胖藥物市場隨著時間的推移經歷了可變的增長。 最近，由於人們對肥胖相關健康風險的認識不斷提高，以及對更有效、更安全的治療方案的需求，人們對這個市場的興趣重新燃起。 市場正在見證新藥的推出，包括聯合療法，旨在改善減肥效果並最大限度地減少副作用。 此外，醫療保健提供者越來越強調全面的肥胖管理方法，包括生活方式改變、行為介入和藥物治療。

此外，全球肥胖盛行率不斷上升以及人們對相關健康風險的認識不斷提高，增加了對有效治療方案的需求。 藥物開發技術的進步為引入具有改善的功效和安全性的新藥提供了機會。 此外，社會對體重管理態度的改變以及對預防性醫療保健的日益重視預計將推動市場成長。 此外，數位健康解決方案和個人化醫療方法的整合提供了一種根據個別患者的需求量身定制治療的途徑，從而擴大了市場範圍。 此外，製藥公司和醫療保健提供者之間的策略聯盟以及研發投資的增加預計將在這個充滿活力和不斷變化的市場格局中提供更多商機。

抗肥胖藥物市場報告重點

2023 年，週邊作用抗肥胖藥物部分由於其機制能夠改善營養吸收和減少飢餓而佔據最大的收入佔有率。

到 2023 年，零售藥局領域將佔據很大的收入佔有率。 這些商店為消費者提供方便的藥物取得服務，並且通常位於社區內交通便利的位置。

2023年，由於肥胖率高以及政府支持政策等多種因素，北美地區佔據了最大的市場佔有率。 此外，製藥巨頭的合併、收購和聯盟等策略性舉措在塑造競爭格□□局方面發揮著至關重要的作用。

目錄

第一章簡介

第 2 章執行摘要

第三章研究方法

第四章全球抗肥胖藥物市場洞察

  • 抗肥胖藥物市場－通路概況
  • 抗肥胖藥物市場動態
    • 推動者和機會
      • 肥胖人數增加
      • 兒童肥胖和病態肥胖的發生率不斷上升
    • 抑制因素和課題
      • 缺乏長期療效數據
  • PESTEL 分析
  • 抗肥胖藥物市場通路趨勢
  • 價值鏈分析
  • 新冠肺炎 (COVID-19) 影響分析

第 5 章依產品劃分的世界市場

  • 主要發現
  • 簡介
  • 非官方
  • 核准

第 6 章以行動方式劃分的世界市場

  • 主要發現
  • 簡介
  • 中樞作用藥物
  • 外周作用藥物

第 7 章依通路劃分的世界市場

  • 主要發現
  • 簡介
  • 醫院藥房
  • 零售藥局
  • 其他

第 8 章依地區劃分的世界市場

  • 主要發現
  • 簡介
    • 2019-2032 年抗肥胖藥物市場評估（依地區）
  • 抗肥胖藥物市場 - 北美
    • 北美：抗肥胖藥物市場（依產品），2019-2032 年
    • 北美：抗肥胖藥物市場，依通路劃分，2019-2032 年
    • 北美：抗肥胖藥物市場（依作用機制），2019-2032 年
    • 抗肥胖藥物市場 - 美國
    • 抗肥胖藥物市場 - 加拿大
  • 抗肥胖藥物市場 - 歐洲
    • 歐洲：抗肥胖藥物市場（依產品），2019-2032 年
    • 歐洲：抗肥胖藥物市場，依通路劃分，2019-2032 年
    • 歐洲：2019-2032 年抗肥胖藥物市場（依作用機轉）
    • 抗肥胖藥物市場 - 英國
    • 抗肥胖藥物市場 - 法國
    • 抗肥胖藥物市場 - 德國
    • 抗肥胖藥物市場 - 義大利
    • 抗肥胖藥物市場 - 西班牙
    • 抗肥胖藥物市場 - 荷蘭
    • 抗肥胖藥物市場 - 俄羅斯
  • 抗肥胖藥物市場 - 亞太地區
    • 亞太地區：抗肥胖藥物市場，分產品，2019-2032 年
    • 亞太地區：抗肥胖藥物市場（依通路），2019-2032 年
    • 亞太地區：2019-2032 年抗肥胖藥物市場（依作用機轉）
    • 抗肥胖藥物市場 - 中國
    • 抗肥胖藥物市場 - 印度
    • 抗肥胖藥物市場 - 馬來西亞
    • 抗肥胖藥物市場 - 日本
    • 抗肥胖藥物市場—印度尼西亞
    • 抗肥胖藥物市場－韓國
  • 抗肥胖藥物市場 - 中東和非洲
    • 中東和非洲：抗肥胖藥物市場（依產品），2019-2032 年
    • 中東與非洲：抗肥胖藥物市場，依通路劃分，2019-2032 年
    • 中東與非洲：抗肥胖藥物市場（依作用機制），2019-2032 年
    • 抗肥胖藥物市場－沙烏地阿拉伯
    • 抗肥胖藥物市場 - 阿聯酋
    • 抗肥胖藥物市場 - 以色列
    • 抗肥胖藥物市場 - 南非
  • 抗肥胖藥物市場 - 拉丁美洲
    • 拉丁美洲：抗肥胖藥物市場（依產品），2019-2032 年
    • 拉丁美洲：抗肥胖藥物市場，依通路劃分，2019-2032 年
    • 拉丁美洲：抗肥胖藥物市場（依作用機制），2019-2032 年
    • 抗肥胖藥物市場 - 墨西哥
    • 抗肥胖藥物市場 - 巴西
    • 抗肥胖藥物市場－阿根廷

第九章競爭態勢

  • 擴張與收購分析
    • 放大
    • 收購
  • 合作/協作/合約/出版物

第十章公司簡介

  • Boehringer Ingelheim International GmbH
  • Currax Pharmaceuticals
  • Gelesis
  • GlaxoSmithKline plc
  • Kintai Therapeutics
  • Novartis AG
  • Novo Nordisk A/S
  • Rhythm Pharmaceuticals, Inc
  • VIVUS LLC
Product Code: PM4814

The global anti-obesity medication market size is expected to reach USD 73,470.85 million by 2032, according to a new study by Polaris Market Research. The report "Anti-Obesity Medication Market Share, Size, Trends, Industry Analysis Report, By Mechanism of Action (Centrally Acting Drugs, Peripherally Acting Drugs); By Product; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Anti-obesity medications are pharmaceutical substances crafted to aid individuals in controlling and reducing their surplus body weight, particularly when lifestyle modifications like dietary adjustments and physical activity alone prove insufficient for attaining and sustaining a healthy weight. These medications can operate through diverse mechanisms, such as modifying metabolism, inhibiting fat absorption, and suppressing appetite. Healthcare providers typically prescribe them to patients meeting specific criteria, such as those with elevated body mass index (BMI) or obesity-related health issues like type 2 diabetes.

The market for anti-obesity medication has experienced variable growth over time, influenced by factors such as shifting societal perceptions regarding weight management, the global escalation in obesity rates, and advancements in pharmaceutical research. In recent times, there has been a resurgence of interest in this market, spurred by heightened awareness of the health hazards linked to obesity and the demand for more efficient and safe treatment options. The market has witnessed the introduction of novel medications, including combination therapies, aimed at improving weight loss outcomes and minimizing adverse effects. Furthermore, healthcare providers are increasingly emphasizing a comprehensive approach to managing obesity, encompassing lifestyle modifications, behavioral interventions, and pharmaceutical treatments.

Additionally, with a rising prevalence of obesity worldwide and an increasing awareness of associated health risks, there is a growing demand for effective treatment options. Advancements in drug development technologies present opportunities for the introduction of novel medications with improved efficacy and safety profiles. Additionally, shifting societal attitudes towards weight management and the growing emphasis on preventive healthcare are expected to drive market growth. Moreover, the integration of digital health solutions and personalized medicine approaches offers avenues for tailoring treatments to individual patient needs, thereby expanding market reach. Furthermore, strategic collaborations between pharmaceutical companies and healthcare providers, as well as increased investment in research and development, are poised to unlock further opportunities in this dynamic and evolving market landscape.

Anti-Obesity Medication Market Report Highlights

In 2023, the peripherally acting anti-obesity drugs segment accounted for the largest revenue share, due to the mechanism's ability to improve nutrient absorption and reduce feelings of hunger.

In 2023, the retail pharmacies segment emerged as the significant revenue share. These outlets provide convenient access to medications for consumers and are commonly located in easily accessible areas within communities.

In 2023, the North American region dominated the largest market share due to various factors, such as the high prevalence of obesity and supportive government policies. Additionally, strategic maneuvers like mergers, acquisitions, and partnerships among pharmaceutical giants play a pivotal role in shaping the competitive landscape.

The global key market players include Boehringer Ingelheim International GmbH, Currax Pharmaceuticals, Gelesis, GlaxoSmithKline plc, Kintai Therapeutics, Novartis AG, Novo Nordisk A/S, Rhythm Pharmaceuticals, Inc., VIVUS LLC.

Polaris Market Research has segmented the Anti-Obesity Medication market report based on mechanism of action, product, distribution channel, and region:

Anti-Obesity Medication, Mechanism of Action Outlook (Revenue - USD Million, 2019 - 2032)

  • Centrally Acting Drugs
  • Peripherally Acting Drugs

Anti-Obesity Medication, Product Outlook (Revenue - USD Million, 2019 - 2032)

  • Off Label
  • Semaglutide (Wegovy)
  • Topiramate (Xenical Alli)
  • Dulaglutide (Trulicity)
  • Liraglutide (Semaglutide (Wegovy))
  • Others
  • Approved
  • Liraglutide (Orlistat)
  • Bupropion-naltrexone (Contrave)
  • Orlistat
  • Alli
  • Xenical
  • Setmelanotide (Imcivree)
  • Tirzepatide (Zepbound)
  • Phentermine-topiramate (Qsymia)
  • Semaglutide (Wegovy

Anti-Obesity Medication, Distribution Channel Outlook (Revenue - USD Million, 2019 - 2032)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Anti-Obesity Medication, Regional Outlook (Revenue - USD Million, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Rest of Asia Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Anti-Obesity Medication Market Insights

  • 4.1. Anti-Obesity Medication Market - Distribution Channel Snapshot
  • 4.2. Anti-Obesity Medication Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. The increasing incidence of obesity
      • 4.2.1.2. A rise in the occurrence of childhood obesity and morbid obesity
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Lack of long-term effectiveness data
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Anti-Obesity Medication Market Distribution Channel Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Anti-Obesity Medication Market, by Product

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • 5.3. Off Label
    • 5.3.1. Global Anti-Obesity Medication Market, by Off Label, by Region, 2019-2032 (USD Million)
    • 5.3.2. Semaglutide (Wegovy)
      • 5.3.2.1. Global Anti-Obesity Medication Market, by Semaglutide (Wegovy), by Region, 2019-2032 (USD Million)
    • 5.3.3. Topiramate (Xenical Alli)
      • 5.3.3.1. Global Anti-Obesity Medication Market, by Topiramate (Xenical Alli), by Region, 2019-2032 (USD Million)
    • 5.3.4. Dulaglutide (Trulicity)
      • 5.3.4.1. Global Anti-Obesity Medication Market, by Dulaglutide (Trulicity), by Region, 2019-2032 (USD Million)
    • 5.3.5. Liraglutide (Semaglutide (Wegovy))
      • 5.3.5.1. Global Anti-Obesity Medication Market, by Liraglutide (Semaglutide (Wegovy)), by Region, 2019-2032 (USD Million)
    • 5.3.6. Others
      • 5.3.6.1. Global Anti-Obesity Medication Market, by Others, by Region, 2019-2032 (USD Million)
  • 5.4. Approved
    • 5.4.1. Global Anti-Obesity Medication Market, by Approved, by Region, 2019-2032 (USD Million)
    • 5.4.2. Liraglutide (Orlistat)
      • 5.4.2.1. Global Anti-Obesity Medication Market, by Liraglutide (Orlistat), by Region, 2019-2032 (USD Million)
    • 5.4.3. Bupropion-naltrexone (Contrave)
      • 5.4.3.1. Global Anti-Obesity Medication Market, by Bupropion-naltrexone (Contrave), by Region, 2019-2032 (USD Million)
    • 5.4.4. Orlistat
      • 5.4.4.1. Global Anti-Obesity Medication Market, by Orlistat, by Region, 2019-2032 (USD Million)
      • 5.4.4.2. Alli
      • 5.4.4.2.1. Global Anti-Obesity Medication Market, by Alli, by Region, 2019-2032 (USD Million)
      • 5.4.4.3. Xenical
      • 5.4.4.3.1. Global Anti-Obesity Medication Market, by Xenical, by Region, 2019-2032 (USD Million)
    • 5.4.5. Setmelanotide (Imcivree)
      • 5.4.5.1. Global Anti-Obesity Medication Market, by Setmelanotide (Imcivree), by Region, 2019-2032 (USD Million)
    • 5.4.6. Tirzepatide (Zepbound)
      • 5.4.6.1. Global Anti-Obesity Medication Market, by Tirzepatide (Zepbound), by Region, 2019-2032 (USD Million)
    • 5.4.7. Phentermine-topiramate (Qsymia)
      • 5.4.7.1. Global Anti-Obesity Medication Market, by Phentermine-topiramate (Qsymia), by Region, 2019-2032 (USD Million)
    • 5.4.8. Semaglutide (Wegovy)
      • 5.4.8.1. Global Anti-Obesity Medication Market, by Semaglutide (Wegovy), by Region, 2019-2032 (USD Million)

6. Global Anti-Obesity Medication Market, by Mechanism of Action

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • 6.3. Centrally Acting Drugs
    • 6.3.1. Global Anti-Obesity Medication Market, by Centrally Acting Drugs, by Region, 2019-2032 (USD Million)
  • 6.4. Peripherally Acting Drugs
    • 6.4.1. Global Anti-Obesity Medication Market, by Peripherally Acting Drugs, by Region, 2019-2032 (USD Million)

7. Global Anti-Obesity Medication Market, by Distribution Channel

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Global Anti-Obesity Medication Market, by Hospital Pharmacies, By Region, 2019-2032 (USD Million)
  • 7.4. Retail Pharmacies
    • 7.4.1. Global Anti-Obesity Medication Market, by Retail Pharmacies, By Region, 2019-2032 (USD Million)
  • 7.5. Others
    • 7.5.1. Global Anti-Obesity Medication Market, by Others, By Region, 2019-2032 (USD Million)

8. Global Anti-Obesity Medication Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Anti-Obesity Medication Market Assessment, By Geography, 2019-2032 (USD Million)
  • 8.3. Anti-Obesity Medication Market - North America
    • 8.3.1. North America: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
    • 8.3.2. North America: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.3.3. North America: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.3.4. Anti-Obesity Medication Market - U.S.
      • 8.3.4.1. U.S.: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.3.4.2. U.S.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.3.4.3. U.S.: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.3.5. Anti-Obesity Medication Market - Canada
      • 8.3.5.1. Canada: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.3.5.2. Canada.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.3.5.3. Canada: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • 8.4. Anti-Obesity Medication Market - Europe
    • 8.4.1. Europe: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
    • 8.4.2. Europe.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.4.3. Europe: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.4.4. Anti-Obesity Medication Market - UK
      • 8.4.4.1. UK: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.4.4.2. UK.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.4.3. UK: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.4.5. Anti-Obesity Medication Market - France
      • 8.4.5.1. France: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.4.5.2. France.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.5.3. France: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.4.6. Anti-Obesity Medication Market - Germany
      • 8.4.6.1. Germany: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.4.6.2. Germany.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.6.3. Germany: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.4.7. Anti-Obesity Medication Market - Italy
      • 8.4.7.1. Italy: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.4.7.2. Italy.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.7.3. Italy: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.4.8. Anti-Obesity Medication Market - Spain
      • 8.4.8.1. Spain: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.4.8.2. Spain.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.8.3. Spain: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.4.9. Anti-Obesity Medication Market - Netherlands
      • 8.4.9.1. Netherlands: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.4.9.2. Netherlands.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.9.3. Netherlands: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.4.10. Anti-Obesity Medication Market - Russia
      • 8.4.10.1. Russia: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.4.10.2. Russia.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.10.3. Russia: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • 8.5. Anti-Obesity Medication Market - Asia Pacific
    • 8.5.1. Asia Pacific: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
    • 8.5.2. Asia Pacific.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.5.3. Asia Pacific: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.5.4. Anti-Obesity Medication Market - China
      • 8.5.4.1. China: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.5.4.2. China.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.4.3. China: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.5.5. Anti-Obesity Medication Market - India
      • 8.5.5.1. India: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.5.5.2. India.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.5.3. India: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.5.6. Anti-Obesity Medication Market - Malaysia
      • 8.5.6.1. Malaysia: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.5.6.2. Malaysia.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.6.3. Malaysia: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.5.7. Anti-Obesity Medication Market - Japan
      • 8.5.7.1. Japan: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.5.7.2. Japan.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.7.3. Japan: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.5.8. Anti-Obesity Medication Market - Indonesia
      • 8.5.8.1. Indonesia: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.5.8.2. Indonesia.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.8.3. Indonesia: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.5.9. Anti-Obesity Medication Market - South Korea
      • 8.5.9.1. South Korea: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.5.9.2. South Korea.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.9.3. South Korea: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • 8.6. Anti-Obesity Medication Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
    • 8.6.2. Middle East & Africa.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.6.3. Middle East & Africa: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.6.4. Anti-Obesity Medication Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.6.4.2. Saudi Arabia.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.6.4.3. Saudi Arabia: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.6.5. Anti-Obesity Medication Market - UAE
      • 8.6.5.1. UAE: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.6.5.2. UAE.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.6.5.3. UAE: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.6.6. Anti-Obesity Medication Market - Israel
      • 8.6.6.1. Israel: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.6.6.2. Israel.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.6.6.3. Israel: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.6.7. Anti-Obesity Medication Market - South Africa
      • 8.6.7.1. South Africa: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.6.7.2. South Africa.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.6.7.3. South Africa: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • 8.7. Anti-Obesity Medication Market - Latin America
    • 8.7.1. Latin America: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
    • 8.7.2. Latin America.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.7.3. Latin America: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.7.4. Anti-Obesity Medication Market - Mexico
      • 8.7.4.1. Mexico: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.7.4.2. Mexico.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.7.4.3. Mexico: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.7.5. Anti-Obesity Medication Market - Brazil
      • 8.7.5.1. Brazil: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.7.5.2. Brazil.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.7.5.3. Brazil: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.7.6. Anti-Obesity Medication Market - Argentina
      • 8.7.6.1. Argentina: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.7.6.2. Argentina.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.7.6.3. Argentina: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Boehringer Ingelheim International GmbH
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Currax Pharmaceuticals
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Gelesis
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. GlaxoSmithKline plc
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Kintai Therapeutics
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Novartis AG
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Novo Nordisk A/S
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Rhythm Pharmaceuticals, Inc
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. VIVUS LLC
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development

List of Tables

  • Table 1 Global Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 2 Global Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 3 Global Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 4 Anti-Obesity Medication Market Assessment, By Geography, 2019-2032 (USD Million)
  • Table 5 North America: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 6 North America: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 7 North America: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 8 U.S.: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 9 U.S.: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 10 U.S.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 11 Canada: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 12 Canada: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 13 Canada: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 14 Europe: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 15 Europe: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 16 Europe: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 17 UK: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 18 UK: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 19 UK: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 20 France: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 21 France: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 22 France: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 23 Germany: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 24 Germany: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 25 Germany: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 26 Italy: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 27 Italy: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 28 Italy: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 29 Spain: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 30 Spain: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 31 Spain: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 32 Netherlands: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 33 Netherlands: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 34 Netherlands: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 35 Russia: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 36 Russia: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 37 Russia: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 38 Asia Pacific: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 39 Asia Pacific: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 40 Asia Pacific: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 41 China: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 42 China: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 43 China: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 44 India: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 45 India: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 46 India: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 47 Malaysia: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 48 Malaysia: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 49 Malaysia: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 50 Japan: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 51 Japan: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 52 Japan: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 53 Indonesia: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 54 Indonesia: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 55 Indonesia: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 56 South Korea: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 57 South Korea: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 58 South Korea: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 59 Middle East & Africa: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 60 Middle East & Africa: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 61 Middle East & Africa: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 62 Saudi Arabia: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 63 Saudi Arabia: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 64 Saudi Arabia: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 65 UAE: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 66 UAE: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 67 UAE: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 68 Israel: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 69 Israel: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 70 Israel: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 71 South Africa: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 72 South Africa: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 73 South Africa: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 74 Latin America: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 75 Latin America: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 76 Latin America: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 77 Mexico: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 78 Mexico: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 79 Mexico: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 80 Brazil: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 81 Brazil: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 82 Brazil: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 83 Argentina: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 84 Argentina: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 85 Argentina: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)

List of Figures

  • Figure 1. Global Anti-Obesity Medication Market, 2019-2032 (USD Million)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Mechanism of Action
  • Figure 7. Global Anti-Obesity Medication Market, by Mechanism of Action, 2022 & 2032 (USD Million)
  • Figure 8. Market by Product
  • Figure 9. Global Anti-Obesity Medication Market, by Product, 2022 & 2032 (USD Million)
  • Figure 10. Market by Distribution Channel
  • Figure 11. Global Anti-Obesity Medication Market, by Distribution Channel, 2022 & 2032 (USD Million)
  • Figure 12. Anti-Obesity Medication Market Assessment, By Geography, 2019-2032 (USD Million)
  • Figure 13. Strategic Analysis - Anti-Obesity Medication Market